REVIEW Landiolol acts as a highly cardioselective, ultra-short-acting beta blocker used as an anti-arrhythmic agent. It was developed for application in the emergency treatment of tachycardia and better control of heart rate in surgery. It is approximately nine times more potent in beta-blocking activity in vivo and eight times more cardioselective in vitro than esmolol. It has a short duration of activity, enabling rapid recovery after cessation of administration if side effects occur. It can be used safely in patients suffering from acute heart disease.
Iguchi, Yoichi; Wakatsuka, Hirohisa Preparation of (2,2-dimethyl-1,3-dioxolan-4S-yl)methyl 3-[4-(2S-hydroxy-3-(2-morpholinocarbonylaminoethyl)aminopropoxyphenyl]propionate hydrochloride as beta1-adrenergic antagonist and its intermediate Jpn. Kokai Tokkyo Koho (1993), JP 05306281 A 19931119.
Iguchi, Sadahiko; Iwamura, Hiroyuki; Nishizaki, Minoru; Hayashi, Akio; Senokuchi, Kazuhiko; Kobayashi, Kaoru; Sakaki, Katsuhito; Hachiya, Katsutoshi; Ichioka, Yumiko; Kawamura, Masanori Development of a highly cardioselective ultra short-acting beta-blocker, ONO-1101 Chemical & Pharmaceutical Bulletin (1992), 40(6), 1462-9.
Yoshiya I.Landiolol hydrochloride, a new sympathetic beta blocker. Masui. 1998 Dec;47 Suppl:S126-32.
Ogata J, Okamoto T, Minami K.Landiolol for the treatment of tachyarrhythmia associated with atrial fibrillation. Can J Anaesth. 2003 Aug-Sep;50(7):753.
These products are explicitly not intended to be used in foods and/or cosmetics and/or drugs (human and veterinary) and/or consumer products and/or biocides and/or pesticides of any kind unless explicitly stated otherwise.
Products are not sold to individuals. We do not ship to residential addresses. Consumer orders will be cancelled without notice.
New customers undergo an internal onboarding process. As part of this process, new customers may be asked for more information. Additional restrictions may apply.